Trial of essiac to ascertain its effect in women with breast cancer (TEA-BC)

Journal of Alternative and Complementary Medicine

Volumn 12, Issue 10, 2006, Pages 971-980

  Zick, Suzanna M ^a   Sen, Ananda ^a   Feng, Yang ^a   Green, Jen ^b   Olatunde, Shade ^c   Boon, Heather ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b University of Toronto ^*

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESSIAC; HERBACEOUS AGENT; RESPERIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ANGER; ANXIETY; ARCTIUM LAPPA; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG INDICATION; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY BREAST CANCER VERSION; HERB; HUMAN; IMMUNE SYSTEM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MOOD; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RETROSPECTIVE STUDY; RHUBARB; RUMEX ACETOSELLA; TASTE DISORDER; TREATMENT OUTCOME; ULMUS FULVA; ULMUS RUBRA; WELLBEING;

EID: 33846211530     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2006.12.971     Document Type: Article

References (44)

1. Collyar D. Breast cancer: A global perspective. J Clin Oncol 2001;19:101s-105s.
2. Mettlin C. Global breast cancer mortality statistics. CA Cancer J Clin 1999;49:138-144.
3. Canadian Cancer Statistics, 2005. Online document at: www.cancer.ca/vgn/images/portal/cit_86751114/48/28/40159 4768cw_2005stats_en.pdf Accessed November 15, 2005.
4. Radice D, Redaelli A. Breast cancer management: Quality-of-life and cost considerations. Pharmacoeconomics 2003;21:383-396.
5. Mosconi P, Colozza M, De Laurentiis M, et al. Survival, quality of life and breast cancer. Ann Oncol 2001;12(suppl 3):S15-S19.
6. Roila F, Cortesi E. Quality of life as a primary end point in oncology. Ann Oncol 2001;12(suppl 3):S3-S6.
7. Goodwin P, Black J, Bordeleau L, et al. Health-related aquality-of-life measurement in randomized clinical trials in breast cancer: Taking stock. J Natl Cancer Inst 2003;95:263-281.
8. Boon H. Use of complementary/alternative medicine by breast cancer survivors in Ontario: Prevalence and perceptions. J Clin Oncol 2000;18:2515-2521.
9. Crocetti E, Crotti N, Feltrin A, et al. The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer 1998;34:324-328.
10. Jacobson J, Verret W. Complementary and alternative therapy for breast cancer: The evidence so far. Cancer Pract 2001;9:307-310.
11. Moschen R, Kemmler G, Schweigkofler H, et al. Use of alternative/ complementary therapy in breast cancer patients-a psychological perspective. Support Care Cancer 2001;9:267-274.
12. Rees R, Feigel I, Vickers A, et al. Prevalence of complementary therapy use by women with breast cancer: a population-based survey. Eur J Cancer 2000;36:1359-1364.
13. Burstein H, Gelber S, Guadagnoli E, et al. Use of alternative medicine by women with early-stage breast cancer. NEJM 1999;340(22):1733-1739.
14. Low Dog T. Traditional and alternative therapies for breast cancer. Altern Ther Health Med 2001;7:36-47.
15. Tamayo C, Richardson M. Presentation at 36th Annual Drug Information Association Meeting. Baltimore, MD, June 17-21, 1999.
16. Eng J. Canadian Cancer Society Information Services: Lessons learned about complementary medicine information needs. Chronic Dis Can 2001;22:3.
17. Kaegi E. Unconventional therapies for cancer: 1. Essiac. Can Med Assoc J 1998;158:897-902.
18. Thomas R. The Essiac report: The True Story of a Canadian Herbal Cancer Remedy and of the Thousands of Lives it Continues to Save, 3rd ed. Los Angeles: Alternative Treatment Information Networks, 1993.
19. Meehan D, Agar J. Doctor's license suspended; some patients still support him. The Grand Rapids Press, April 18, 1997:12.
20. Farragher B. Psychiatric morbidity following the diagnosis and treatment of early breast cancer. Ir J Med Sci 1998;167:166-169.
21. Brady M. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast Quality of Life instrument. J Clin Oncol 1997;15:974-986.
22. McNair D, Lorr M, Droppleman LF. Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Services, 1971.
23. Koopman C, Hermanson K, Diamond S, et al. Social support, life stress, pain and emotional adjustment to advanced breast cancer. Psycho-oncology 1998;7:101-111.
24. Zittoun R, Achard S, Ruszniewski M. Assessment of quality of life during intensive chemotherapy or bone marrow transplantation. Psycho-oncology 1999;8:64-73.
25. Breast Cancer, Facts and Figures 2001-2002. Online document at: www.cancer.org/downloads/STT/BrCaFF2001.pdf Accessed June 2005.
26. Box GEP, Cox DR. An analysis of transformations (with discussion). J R Stat Soc B 1964;26:211-252.
27. Cella D, Eaton D, Lai J, et al. Combining Anchor and Distribution-based methods to derive minimal clinincally important differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue Scales. J Pain Symptom Manage 2002;24:547-561.
28. Ashikaga T, Bosompra K, O'Brien P, et al. Use of complementary and alternative medicine by breast cancer patients: Prevalence, patterns and communication with physicians. Support Care Cancer 2002;10:542-548.
29. Lengacher CA, Bennett MP, Kip KE, et al. Frequency of use of complementary and alternative medicine in women with breast cancer. Oncol Nurs Forum 2002;29:1445-1452.
30. Molassiotis A, Scott JA, Kearney N, et al. Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer 2006;14:260-267.
31. Yap KP, McCready DR, Fyles A, et al. Use of alternative therapy in postmenopausal breast cancer patients treated with tamoxifen after surgery. Breast J 2004;10:481-486.
32. Cui Y, Shu X-O, Gao Y, et al. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res Treat 2004;241:1-8.
33. Rakovitch E, Pignol JP, Chartier C, et al. Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. Breast Cancer Res Treat 2005;90:139-148.
34. Nagel G, Hoyer H, Katenkamp D. Use of complementary and alternative medicine by patients with breast cancer: Observations from a health-care survey. Support Care Cancer 2004;12:789-796.
35. Russfield A. Pathology Report, Project No C-144 [Essiac Experiments]. Cambridge, MA: Bio-Research Consultants, Inc., October 8, 1959.
36. Tai J, Cheung S, Wong S, et al. In vitro comparison of Essiac and Flor-Essence on human tumor cell lines. Oncol Rep 2004;11:471-476.
37. U.S. Congress Office of Technology Assistance. Unconventional Cancer Treatments [OTA-H-405]. Washington, DC: U.S. Government Printing Office, 1990:71-75.
38. LeMoine L. Essiac: An historical perspective. Can Oncol Nurse J 1997;7:216-221.
39. Richardson M. Flor-Essence herbal tonic use in North America: A profile of general consumers and cancer patients. HerbalGram 2000;50:40-46.
40. Kaegi E. Essiac: An Information Package. Toronto: CBCRI, 1996.
41. Gray C. Laetrile: Canada's legal position firm but pressure in the South grows. Can Med Assoc J 1997;117:1068-1074.
42. Essiac: An ineffective cancer treatment. Ottawa, Ontario, Canada; Health and Welfare: Canada HaW, Health Protection Branch, February 7, 1989.
43. Shen J, Andersen R, Albert PS, et al. Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med 2002;2:8.
44. Salmenpera L. The use of complementary therapies among breast and prostate cancer patients in Finland. Eur J Cancer Care (Engl) 2002;11:44-50.